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Abstract 
Objective: To assess changes in insulin resistance and β-cell function in a multiethnic cohort of 
women in Oslo, Norway, from early to 28 weeks’ gestation and three months postpartum, and relate 
the findings to gestational diabetes (GDM). 
Method: Population-based cohort study of 695 healthy pregnant women from Western Europe (41%), 
South Asia (25%), Middle East (15%), East Asia (6%) and elsewhere (13%). Blood samples and 
demographics at mean 15 (V1) and 28 (V2) weeks' gestation, and 3 months postpartum (V3). 
Universal screening by 75-g oral glucose tolerance test at V2, GDM with modified IADPSG criteria 
(no 1-hour measurement): Fasting Plasma Glucose (FPG) ≥5.1 or 2-hour PG ≥8.5 mmol/l. HOMA-β 
(β-cell function) and HOMA-IR (insulin resistance) calculated from fasting glucose and C-peptide.  
Result: Characteristics were comparable across ethnic groups, except age (South Asians: younger, 
P<0.001) and prepregnant BMI (East Asians: lower, P=0.040). East and South Asians were more 
insulin resistant than Western Europeans at V1. From V1-V2 the increase in insulin resistance was 
similar across the ethnic groups, but the increase in β-cell function was significantly lower for the East 
and South Asians compared with Western Europeans. GDM compared with non-GDM women were 
more insulin resistant at V1, from V1-V2 their β-cell function increased significantly less and the 
percentage increase in β-cell function did not match the change in  insulin resistance. 
Conclusion: Pregnant women from East Asia and South Asia were more insulin resistant and showed 
poorer HOMA-β-cell function than Western Europeans. 
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Introduction 
During pregnancy, insulin resistance is reported to increase by 50-60% to secure shunting of nutrients 
to the foetus (1). This increase is mediated partly through secretion of  hormones from the placenta 
and increase in body fat depots (2). Β-cells increase their insulin production through hyperplasia, 
hypertrophy and hyperfunction to compensate for the pregnancy induced insulin resistance in healthy 
women. The Homeostatic Model Assessment (HOMA) provides estimates of insulin resistance and 
gives an indication of the insulin secretion from fasting blood sample values (3). If the insulin 
secretion is inadequate to meet the insulin demands, maternal hyperglycaemia may ensue (2). 
Glucose intolerance with onset or first recognition during pregnancy is known as gestational diabetes 
mellitus (GDM) (2). The initial GDM criteria were established in 1964, and primarily set to predict 
future diabetes in the mother (4, 5). The most frequently used GDM criteria today, are with only minor 
modifications similar to the initial GDM criteria or adopted from standards used outside pregnancy 
(6). Hence, GDM screening is thought to identify women with a failing β-cell function at high risk for 
the development of diabetes later in life (2). 
The Hyperglycaemia and Adverse Pregnancy Outcome (HAPO) study was conducted to clarify 
unanswered questions of the associations between maternal glycaemia and the risk of adverse 
outcomes (7). The HAPO-study’s main findings were a continuous linear relationship between 
maternal glycaemia and adverse foetal outcomes defined as >90
th
 percentiles of birth weight, percent 
body fat and cord C-peptide (7, 8). 
Based on the findings from the HAPO-study, the International Association of Diabetes in Pregnancy 
Study Groups (IADPSG) have proposed new criteria for GDM (8). The IADPSG criteria were defined 
to identify women with an odds ratio of 1.75 for adverse foetal outcomes. Compared with the WHO 
criteria, the cut-off values in the IADPSG criteria are lowered for fasting plasma glucose (FPG) and 
raised for 2-hour plasma glucose (PG) (5, 8). One abnormal glucose value is adequate for the IADPSG 
GDM diagnosis, and the majority of cases are reported to be identified by the FPG cut-off value (8-
10). The IADPSG criteria thus identify some women who have not previously been identified with 
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GDM (11). An important question is to which degree the IADPSG criteria identify women with a 
failing β-cell function and therefore at risk for future diabetes. 
We recently reported that the prevalence of GDM with both the WHO and the modified IADPSG 
criteria were high for Western European and immigrant women living in Oslo (9). GDM is increasing 
in line with the diabetes type 2 prevalence worldwide (12, 13).  Ethnic minority groups in Western 
countries are more insulin resistant and have higher diabetes prevalence rates compared with the host 
population (14).  It is unclear if the relationship between the pregnancy induced insulin resistance and 
the β-cell function differ across ethnic groups. 
The aim of the present study was to assess the changes in insulin resistance and β-cell function by 
HOMA in a multiethnic cohort of women from early gestation to 28 weeks of gestation and three 
months postpartum, and further to assess how this appears in GDM women identified with the 
IADPSG criteria, modified due to lack of 1 hour glucose values. 
Subjects and methods 
Study population and data collection 
The Stork Groruddalen Study is a population-based cohort study that collected data at three public 
Child Health Clinics (CHC) in Eastern Oslo, Norway, from May 6th 2008 to May 15th 2010 (15). The 
Regional Ethics committee and The Norwegian Data Inspectorate approved the study protocol. The 
methods are described in details elsewhere (9, 15).  Women were eligible if they 1) lived in the 
districts, 2) planned to give birth at one of two study hospitals, 3) were in <20 weeks of gestation at 
visit 1 (V1), 4) could communicate in Norwegian, Arabic, English, Sorani, Somali, Tamil, Turkish, 
Urdu or Vietnamese and 5) were able to give a written consent to participate. Women with 
pregestational diabetes or other diseases necessitating intensive hospital follow-up during pregnancy, 
were excluded. Women were followed up at 28±2 weeks of gestation (V2) and three months 
postpartum (V3).  Staff members were certified after training, and assisted by professional translators 
when needed. Questionnaire data through interviews (demographics), anthropometric measurements 
(body height (fixed stadiometer), body weight (Tanita BC 418MA, Tokyo, Japan)) and venous fasting 
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blood samples were collected at V1-V3.  A 75 g oral glucose tolerance test (OGTT) was performed at 
V2. Ethnic origin was defined by country of birth of the participant, or that of the participant’s mother 
if the participant’s mother was born outside Europe or North America (9). 
From the total cohort of 823 (74% of the invited) women originally included in the STORK-
Groruddalen study, 772 attended V2 (9). Totally 695 singleton pregnant women with available fasting 
glucose and C-peptide values from both V1 and V2 were included in the present study and constitute 
the study population. Five hundred and ninety-six of these women attended V3 where 523 delivered 
fasting blood samples to estimate HOMA-values. The reduced number at V3 was mainly due to 
resource limitations at the CHC, however, ethnic minority women and those with GDM with the 
WHO criteria were prioritized. 
Laboratory methods 
All glucose values were measured from venous blood on gel tubes, allowed to clot for 30 minutes 
before cells were separated from serum, stored at +4
ο
C and daily shipped and handled at the 
Department of Multidisciplinary Laboratory Medicine and Medical Biochemistry, Akershus 
University Hospital  (Vitros 5.1 FS, Ortho Clinical Diagnostics, slide adapted colorimetric method)). 
Glycated hemoglobin (HbA1c) was measured with HPLC (Tosoh G8, Tosoh Corporation, normal 
reference range 4-6%). Fasting C-peptide and Insulin was measured at the Hormone Laboratory, Oslo 
University Hospital by non-competitive immunofluorometric assays (DELFIA, PerkinElmer Life 
Sciences, Wallac Oy, Turku, Finland).  FPG and 2-hour PG for the diagnosis of GDM at V2 was 
measured on site in venous EDTA blood (HemoCue 201+, Angelholm, Sweden) (9). 
GDM was diagnosed at V2 when FPG ≥5.1 mmol/l or 2-h PG ≥8.5 mmol/l according to a modified 
version of the IADPSG criteria, as one hour glucose values were not available (8).  Insulin resistance 
(HOMA-IR) and β-cell function (HOMA-β) were estimated by the Oxford University HOMA 
Calculator 2.2 with fasting glucose and C-peptide concentrations (16). 
Statistical analyses 
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Differences in characteristics between groups were tested with t-tests and one-way ANOVA for 
normally distributed, and Mann-Whitney U and Kruscal-Wallis test for non-normally distributed 
continuous variables, presented as mean with standard deviation (S.D.) or median with inter quartile 
range [IQR] as appropriate. The Sign test was used for related samples and the exact p-values were 
reported. Statistical significance was set at a 2-tailed probability level of p<0.05 and Bonferroni-
corrections for multiple testing were used. SPSS version 19 was used for all analyses. 
The percentage change in the HOMA values from V1 to V2 were calculated by the formula (
(HOMA at V2 
– HOMA at V1)/HOMA at V1)*100. Univariate and multiple linear regression analyses were performed with 
HOMA-IR at V1 and percentage change in HOMA-β from V1 to V2 as dependent variables. The 
dependent variables were adjusted for gestational week at inclusion and ethnic origin in Model 1 and 
in addition prepregnant BMI in Model 2. The residuals were checked for normality and independence. 
Sensitivity analyses in non-GDM women only were done to test the robustness of the findings.  
Univariate and multiple logistic regression analyses were performed to identify the effect of HOMA-
IR at V1 and percentage change in HOMA-β from V1 to V2 on GDM separately, after adjustments for 
gestational week at inclusion, prepregnant BMI and ethnic origin. 
The reference group was Western Europe, mainly women from Norway (93%) and Sweden/Denmark 
(4%). The ethnic minority groups were; South Asia mainly from Pakistan (62%) and Sri Lanka (31%); 
Middle East mainly from Iraq (28%), Turkey (23%) and Morocco (21%); East Asia mainly from 
Vietnam (44%) and Philippines (28%); and Others from Sub-Saharan Africa (mainly Somalia (62%) 
and Nigeria (7%)) and other ethnic minorities (Eastern Europe and South- and Central America). 
Results 
The mean (S.D.) maternal age was 29.8 years (4.9), and the prepregnant BMI 24.5 kg/m2 (4.8) (Table 
1). East Asian women had lower prepregnant BMI compared with the Western European women 
(P=0.040). Women from South Asia were younger (P<0.001), and like the East Asian and African 
women they were recruited into the study slightly later in pregnancy compared with Western 
Europeans (P≤0.001). The East Asians had higher 2-hour glucose values at V2 than the Western 
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Europeans (P=0.06). The proportion identified with GDM with the modified IADPSG criteria was for 
Western Europeans 25%, South Asians 40%, Middle Easterners 37%, Sub-Saharan Africans 41% and 
East Asians 28%.  There were no statistically significant difference between the 695 women included 
and the 128 women excluded from the present study with respect to ethnic origin (Western Europe vs. 
Ethnic minority), age, parity, prepregnant BMI, body height or level of education. 
The overall insulin resistance measured by HOMA-IR increased from median [IQR] 1.1 [0.6] at V1 to 
1.7 [0.9] at V2 (P<0.001). South Asians had higher HOMA-IR compared with Western Europeans, at 
V1 (1.2 vs. 1.0, P<0.001) and V2 (1.8 vs.1.5, P<0.001) (Fig 1a). There were no statistically significant 
differences between the ethnic groups in the absolute or percentage change in HOMA-IR from V1 to 
V2 (Table 2). 
The overall β-cell function measured by HOMA-β increased from 133.2 [42.6] at V1 to 173.5 [49.3] at 
V2 (P<0.001). South Asians had higher HOMA-β compared with Western Europeans at V1 (143.6 vs. 
125.9, P<0.001), but not at V2 (178.6 vs. 172.6, P=0.25) (Fig 1b). The absolute and percentage change 
in HOMA-β from V1 to V2 was less for the South Asian (P<0.005) and East Asian (P<0.002) 
compared with the Western European women (Table 2). 
Linear regression analyses with HOMA-IR at V1 as the dependent variable revealed that South Asian 
and Middle Eastern women were more insulin resistant compared with Western Europeans in early 
gestation also after adjustments for gestational week at inclusion (Model 1; Table 3a). After further 
adjustments for prepregnant BMI, this difference in HOMA-IR was no longer found for the Middle 
Easterners, it was still present for the South Asians, while the East Asians became significantly more 
insulin resistant (Model 2). The findings still persisted after additional adjustments for parity and 
family history of diabetes (data not shown).  
With the percentage change in HOMA-β from V1 to V2 as the dependent variable, the lesser increase 
in β-cell function among the East Asian and South Asian compared with the Western European 
women persisted after adjustments for gestational week at inclusion (Model 1; Table 3b), and with 
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further adjustments for prepregnant BMI (Model 2). The findings still persisted after additional 
adjustments for parity and family history of diabetes (data not shown).  
The mean prepregnant BMI was significantly higher in women with GDM compared with women 
with normal glucose levels (Table 4). Their mean increase in BMI units from prepregnancy to V2 was 
similar (p=0.760). Women with GDM compared with women without GDM, were more insulin 
resistant, measured by HOMA-IR, at V1 (1.3 vs. 1.0, P<0.001) and V2 (2.0 vs. 1.5, P<0.001) (Fig 2a), 
but their β-cell function, measured by HOMA-β, was similar at V1 (136.3 vs. 132.0) and lower at V2 
(166.7 vs. 176.5, P=0.003) (Fig 2b). The absolute change in HOMA-IR from V1 to V2 was 
significantly higher for the GDM compared with non-GDM women, but the percentage change was 
similar (Table 4). The absolute and percentage change in HOMA-β from V1 to V2 was significantly 
less in the GDM compared with the non-GDM women. Logistic regression analysis revealed that there 
was a highly significant increased odds ratio (OR) for GDM per unit increase in HOMA-IR at V1, also 
after adjustments for gestational week, prepregnant BMI and ethnic origin, OR 4.62 (95% CI 3.00–
7.12).  Per percentage increase in HOMA-β from V1 to V2 gave a highly significant protective OR for 
GDM, also after adjustments as previous, 0.99 (0.98-0.99). 
At V3, the South Asian women had higher HOMA-IR and HOMA-β compared with the Western 
Europeans (P<0.001) (Table 5). For the GDM compared with non-GDM women at V3, the BMI was 
27.5 kg/m
2
 (5.3) vs. 25.3 kg/m
2 
(4.5) 
  
(P<0.001), the HOMA-IR 1.7 [0.95] vs. 1.2 [0.66] (P<0.001) 
and the HOMA-β 129.4 [52.5] vs. 123.0 [38.8] (P=0.029). At V3 the GDM women had higher mean 
HbA1c and fasting glucose values compared with the non-GDM women 5.5% (0.3) vs. 5.4% (0.3) and 
5.0 mmol/l (0.5) vs. 4.7 mmol/l (0.4) (both P<0.001), but no women had fasting glucose ≥7mmol/l or 
HbA1c ≥6.5%.  There were no significant differences between the 523 women with and the 180 
women without HOMA values at all three visits with respect to age, parity, prepregnant BMI, level of 
education or GDM with the modified IADPSG criteria. 
Discussion 
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The prevalence of GDM and type 2 diabetes varies between ethnic groups, and is reported to be high 
in immigrants from Asia (12-14, 17). However, few studies have compared insulin resistance and β-
cell function during pregnancy in a multiethnic cohort. In the present study we found that the East 
Asian and South Asian women were more insulin resistant in early pregnancy compared with Western 
Europeans, and the differences were larger after adjustments for BMI. From early to 28 weeks of 
gestation, all women irrespective of ethnic origin and baseline level became equally more insulin 
resistant. During the same period, the β-cell function to the East Asian and South Asian women did 
not compensate to the same extent as the Western Europeans. Women identified with GDM with the 
modified IADPSG criteria were more insulin resistant and their β-cell function was not able to meet 
the insulin demands induced by the pregnancy. 
Insulin resistance is impinged by adiposity, and overweight and obese women start their pregnancy 
more insulin resistant compared with normal weight women (1). In the present study, a higher mean 
BMI explained the increased insulin resistance found in the Middle Eastern women. Middle Eastern 
women were also in previous studies identified with higher BMI levels than women from other ethnic 
groups (14, 18). On the other hand, the East Asian and South Asian women were more insulin resistant 
after adjustments for BMI compared with the Western Europeans. Asians are known to have more fat 
per BMI unit compared with Western subjects (14, 19-21). This may contribute to increased insulin 
resistance which is especially shown in South Asians (19, 20, 22). An increase in insulin resistance is a 
normal physiological phenomenon during pregnancy (1). Regardless of ethnic origin and baseline 
level, the insulin resistance increased approximately 40-45% from early to 28 weeks of gestation, a 
finding that is in concert with previous reports (1). 
To maintain normoglycaemica during pregnancy, an increase in insulin secretion is needed to 
compensate for the increased insulin resistance (2). The precise mechanisms of β-cells mass expansion 
during human pregnancy have only partially been elucidated, but reports indicate that there is an 
adaptive increase in β-cell numbers (23-25). From early to 28 weeks of gestation the women from 
South Asia were not able to increase their β-cell function mutual to the insulin resistance. The β-cell 
response relative to the pregnancy induced insulin resistance was therefore unbalanced compared with 
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the Western Europeans. Reduced levels of adiponectin, a hormone secreted from adipose tissue and 
the placenta are in pregnancy associated with β-cell dysfunction (26). Pregnant women from South 
Asia are reported to have hypoadiponectinaemia to a greater extent compared with Caucasians (27), 
but this needs to be explored further. 
The women from East Asia, like the South Asians, showed less increase in β-cell function from early 
to 28 weeks of gestation compared with the Western Europeans. Even though there were no statistical 
significant ethnic differences in the increase in the insulin resistance during the same period of time, 
the East Asians showed numerically less increase. Their increase in β-cell response relative to the 
increase in insulin resistance was therefore more in balance compared with the South Asians. East 
Asian subjects have in previous studies shown marked postprandial hyperglycaemia compared with 
matched Caucasian subjects (17, 18, 28), and might therefore be more predisposed to peripheral 
insulin resistance (29). Our results are in line with these findings, as the East Asian women showed a 
lesser degree of fasting hyperglycaemia, and higher 2-hour glucose values (9). The HAPO-study has 
also reported that GDM women in East Asia (Bangkok and Hong Kong) were less likely to be 
diagnosed based on the FPG value compared with women at other HAPO-study sites (10). 
GDM screening with the most frequently used GDM criteria today (6, 12), is thought to identify 
women with an underlying β-cell defect not able to handle the metabolic stress that occurs during 
pregnancy (2). In the present study, using the modified IADPSG criteria, the GDM women were much 
more insulin resistant in early and at 28 weeks of gestation compared with the non-GDM women. 
However, in line with other studies, the percentage increase in insulin resistance was similar (1). The 
GDM women had poorer β-cell function at 28 weeks of gestation, and showed inequality between the 
increase in insulin resistance and β-cell response from early to 28 weeks of gestation, compared with 
the non-GDM women. Impaired fasting glucose, at least outside pregnancy, is suggested to be an 
effect of hepatic insulin resistance (29). Further, it has been reported that elevated endogenous glucose 
production, pointing to hepatic insulin resistance during pregnancy may lead to the development of 
type 2 diabetes. This together with our results could indicate that the IADPSG criteria, primarily set to 
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prevent adverse foetal outcomes (7), also identify women with a β-cell dysfunction at risk for 
developing diabetes later in life (30). 
The South Asians were more insulin resistant and had elevated β-cell function compared with the 
Western Europeans three months postpartum, similar to the differences found at V1. No women 
qualified for a diagnosis of diabetes by using either FPG or HbA1c-criteria. The GDM women were 
more insulin resistant compared to the non-GDM women three months postpartum, but the β-cell 
function did not seem to differ to the same extent. The GDM women’s higher fasting glucose and 
HbA1c values might indicate that their β-cell function in relation to the higher insulin resistance was 
inappropriate, and could therefore be a sign of relative β-cell failure. It has been reported that GDM 
women seem able to compensate for the increased insulin resistance in the first months postpartum, 
but that they may manifest progressive loss of β-cell function in the long run (2). Severe hepatic 
insulin resistance, which is linked to elevated FPG (29) is reported to deteriorate β-cell function in the 
first year postpartum after gestational dysglycaemia (31).  Recent reports indicate that subjects with 
elevated FPG have impaired first-phase insulin secretion and therefore β-cell failure (32). 
Although no significant differences between those who did and did not attended V3 were found, we 
can not rule out that selection bias might have affected the results three months postpartum. The Stork 
Groruddalen study was not purely observational as 13% of the women identified with GDM with the 
WHO criteria received lifestyle advice at 28 weeks of gestation (9). The Stork Groruddalen study was 
planned prior to the announcement of the IADPSG criteria and used the WHO criteria with fasting and 
2-hour glucose values to diagnose GDM according to Norwegian standards. The lack of the 1-hour 
glucose value is therefore an additional limitation of the present study. However, the majority of 
women identified with GDM with the IADPSG criteria in previouse studies are identified with the 
FPG value. Due to limited resources and the wish to include a high percentage of women from all 
ethnic groups, the recourse intensive “gold standard” methods, clamp studies or intravenous glucose 
tolerance tests, to quantify insulin resistance and β-cell function in vivo, were not feasible. The 
HOMA is a surrogate measure of these parameters, estimated from fasting glucose and insulin or C-
peptide concentrations (3). HOMA-β has therefore limited ability to detect chronic β-cell dysfunction, 
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and might explain the absence of a difference in β-cell function between the GDM and non-GDM 
women in early gestation. However, HOMA is feasible in large studies and has also been validated in 
studies of pregnant women (16, 33, 34). 
The strength of this study is the follow-up design and high response rate both during and after 
pregnancy across the ethnic groups (9, 15). It is important to characterise the diabetes pathogenesis 
and ethnic differences in order to curb the diabetes pandemic, where Asians are especially affected 
(12, 13).  Asians are the fastest growing minority group in the US, and South Asians the largest 
minority group in several European countries (20). The results from the present study should therefore 
be relevant outside the Norwegian context as the sample is fairly representative for the largest ethnic 
groups included (9). 
Conclusion 
We found ethnic differences in insulin resistance and β-cell function measured by HOMA, through 
pregnancy and three months postpartum. East Asian and South Asian women were more insulin 
resistant compared with Western Europeans after adjustments for BMI, and showed poorer β-cell 
function. GDM diagnosed with modified IADPSG criteria was associated with less ability to 
compensate to the pregnancy-induced insulin resistance. We therefore conclude that the IADPSG 
criteria, primarily set to prevent adverse foetal outcomes, may also identify women with a latent β-cell 
failure presumably at risk of future diabetes. 
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Table 1 Characteristics of the total cohort, and stratified into ethnic groups. Values are mean and standard deviation (S.D.) or otherwise stated.  
 
Total  
n=695 (100 %) 
Western Europe 
n=286 (41 %) 
South Asia  
n=174 (25 %) 
Middle East  
n=105 (15 %) 
Sub-Saharan 
Africa  
n=42 (6 %) 
East Asia 
 n=39 (6 %) 
Others  
n=49 (7 %) 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Age, years 29.8 4.9 30.9 4.5 28.6 4.4 29.3 5.4 27.9 5.3 31.0 4.6 29.3 5.2 
Body height, cm 163.6 6.7 167.3 5.6 160.1 5.7 161.2 5.5 162.6 6.1 157.0 6.4 165.5 6.3 
BMI prepregnancy, kg/m
2
 24.5 4.8 24.7 4.9 23.6 4.1 25.7 5.1 26.1 5.4 22.3 3.4 24.7 5.2 
Visit 1                       
Weeks of gestation 15 3 14 2 15 4 15 3 17 4 17 4 15 3 
Weight, kg 67.6 14.1 70.9 14.0 62.0 11.4 69.6 15.2 71.1 14.6 57.0 10.6 69.5 14.0 
BMI, kg/m
2
 25.2 4.8 25.3 4.8 24.2 4.0 26.7 5.4 26.8 5.0 23.1 3.6 25.4 4.9 
HbA1c , % 5.2 0.3 5.2 0.2 5.2 0.3 5.1 0.3 5.2 0.3 5.2 0.4 5.1 0.3 
Fasting glucose, mmol/l 4.4 0.4 4.4 0.4 4.5 0.4 4.5 0.5 4.4 0.5 4.3 0.3 4.4 0.4 
Insulin, pmol/la 40.0 33.0 32.0 26.0 52.5 40.0 40.0 35.0 43.0 49.0 39.0 26.0 37.0 32.0 
C-peptide, nmol/l
a
 0.52 0.26 0.48 0.23 0.59 0.30 0.52 0.27 0.48 0.29 0.53 0.22 0.51 0.23 
Visit 2                       
Weeks of gestation 28 1 28 1 28 1 28 1 28 1 28 1 28 1 
Weight, kg 74.3 14.0 77.5 13.9 68.7 11.6 76.7 14.7 76.0 14.97 63.2 10.3 77.6 12.6 
BMI, kg/m
2
 27.7 4.6 27.7 4.7 26.8 4.0 29.5 5.1 28.7 5.1 25.6 3.4 28.3 4.4 
HbA1c , % 5.2 0.3 5.1 0.3 5.3 0.3 5.2 0.4 5.3 0.3 5.2 0.3 5.2 0.3 
Fasting glucose, mmol/l 4.4 0.5 4.4 0.5 4.5 0.5 4.5 0.6 4.4 0.6 4.4 0.4 4.4 0.6 
2-h glucose, mmol/l 5.7 1.5 5.6 1.4 5.9 1.6 5.9 1.7 5.5 1.3 6.3 1.5 5.7 1.5 
Insulin, pmol/l
a
 57.0 44.0 48.0 36.0 75.0 42.0 60.0 46.0 62.0 52.0 52.0 35.0 56.0 38.0 
C-peptide, nmol/la 0.76 0.39 0.71 0.34 0.86 0.39 0.76 0.46 0.74 0.35 0.71 0.35 0.73 0.27 
a median, IQR  
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Table 2 Absolute (∆) and percentage change (%∆) in biochemical parameters and HOMA values from visit 1 to visit 2 in study participants according to 
ethnic group. Values in median and Inter Quartile Range (IQR) or otherwise stated.  
  
Western Europe South Asia Middle East Sub-Saharan Africa East Asia Others 
Median IQR Median IQR Median IQR Median IQR Median IQR Median IQR 
∆ Fasting glucose
a
, 
mmol/l 
-0.1 0.4 0.0 0.4 0.1 0.5 0.0 0.6 0.0 0.4 0.0 0.5 
∆ Insulin, pmol/l 13.0 25.0 18.0 34.0 15.0 30.0 10.5 35.0 12.0 29.0 19.0 32.0 
∆ C-peptide, nmol/l 0.22 0.25 0.24 0.28 0.22 0.30 0.16 0.31 0.19 0.20 0.22 0.25 
∆ HOMA-IR  0.45 0.54 0.50 0.58 0.47 0.70 0.32 0.69 0.42 0.52 0.45 0.45 
∆ HOMA-β  43.5 39.5 32.5** 45.1 35.9 43.8 37.2 46.0 23.8** 45.3 46.0 43.9 
% ∆ HOMA-IR 46.0 57.6 43.0 56.1 43.6 66.8 31.5 76.5 33.2 40.3 47.7 75.0 
% ∆ HOMA-β 33.6 35.7 22.9** 33.7 31.3 32.0 29.4 43.7 17.8* 36.5 34.4 31.6 
a  mean. S.D. * p<0.05 difference from Western European, Bonferroni corrected ** p< 0.005 difference from Western European, Bonferroni corrected. 
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Table 3 Linear regression analyses with a) HOMA-IR at visit 1 (V1) and b) percentage change (%∆) in HOMA-β from V1 to visit 2 as the dependent variable.
 Univariate Multiple Model 1
a Multiple Model 2b 
  β-Coefficient p-value β-Coefficient p-value β-Coefficient p-value 
a) V1 HOMA-IR       
Weeks of gestation V1 0.02 <0.001 0.02 0.001 0.02 0.002 
South Asia 0.29 <0.001 0.27 <0.001 0.33 <0.001 
Middle East 0.11 0.046 0.10 0.086 0.05 0.271 
East Asia 0.11 0.171 0.07 0.422 0.19 0.009 
Others 0.04 0.468 0.01 0.810 -0.02 0.735 
BMI prepregnancy 0.05 <0.001   0.05 <0.001 
b)  %∆ HOMA-β       
Weeks of gestation V1 -2.20 <0.001 -2.00 <0.001 -1.73 <0.001 
South Asia -12.28 0.003 -10.00 0.015 -11.05 0.005 
Middle East -5.74 0.237 -4.15 0.390 -3.36 0.432 
East Asia -20.68 0.005 -16.08 0.028 -19.27 0.006 
Others -0.63 0.902 2.16 0.673 -0.69 0.889 
BMI prepregnancy -0.98 0.003   -1.14 0.001 
 
                                                            
a
 adjusted for weeks of gestation at V1 and ethnic origin with Western Europe as reference 
b
 additional adjustments for  prepregnant BMI 
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Table 4 Characteristics and biochemical parameters at visit 1 (V1), and absolute (∆) and percentage change (%∆) from V1 to visit 2 for the GDM and non-
GDM women. Values in mean and standard deviation (S.D.), median and Inter Quartile Range (IQR) or otherwise stated. P-values for the difference between 
the groups. 
 
 
GDM 
n=220 (32%) 
Non-GDM 
n=475 (68%) 
 
 Mean S.D. Mean S.D. p-value 
Weeks of gestation at V1 15 3 15 3 0.905 
Age, years 30.2 5.1 29.6 4.7 0.176 
BMI prepregnancy, kg/m
2
 25.9 5.5 23.9 4.2 <0.001 
Body height, cm 162.9 6.6 163.9 6.7 0.071 
Weight, kg 70.7 16.2 66.2 12.9 <0.001 
HbA1c, % 5.3 0.3 5.1 0.3 <0.001 
Fasting glucose, mmol/l 4.7 0.4 4.3 0.3 <0.001 
Insulinb, pmol/l 55.0 47.0 36.0 26.0 <0.001 
C-peptide
b
, nmol/l 0.63 0.35 0.48 0.21 <0.001 
 Median IQR Median IQR p-value 
∆ Weighta, kg 6.8 3.3 6.6 3.0 0.557 
∆ Fasting glucose a, mmol/l 0.2 0.5 -0.1 0.4 <0.001 
∆ Insulin, pmol/l 19.0 34.0 12.0 26.0 0.008 
∆ C-peptide, nmol/l 0.26 0.28 0.20 0.24 <0.001 
∆ HOMA-IR  0.6 0.7 0.4 0.5 <0.001 
∆ HOMA-β  30.0 40.8 43.5 40.1 <0.001 
% ∆ HOMA-IR 47.5 63.3 41.4 57.6 0.161 
% ∆ HOMA-β 21.9 32.5 32.9 35.3 <0.001 
a
 mean, S.D. 
b 
median, IQR   
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Table 5 Post-partum characteristics, biochemical parameters and HOMA values of the total cohort, and stratified into ethnic groups. Values are mean and 
standard deviation (S.D.) or otherwise stated.  
 
Total  
n=523 (100 %) 
Western Europe 
n=203 (39 %) 
South Asia  
n=141 (27 %) 
Middle East  
n=85 (16 %) 
Sub-Saharan 
Africa n=26 (5 %) 
East Asia 
 n=31 (6 %) 
Others  
n=37 (7 %) 
Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Weeks postpartum 14 3 14 2 14 3 14 3 15 3 15 3 14 2 
Weight, kg 69.7 14.3 72.1 14.7 65.4 11.5 72.3 15.8 73.1 13.8 59.5 10.0 71.3 13.6 
BMI, kg/m
2
 26.0 4.9 25.7 5.0 25.5 4.2 27.8 5.3 28.1 5.0 24.0 3.3 26.1 4.9 
HbA1c , % 5.4 0.3 5.4 0.2 5.5 0.3 5.3 0.3 5.5 0.3 5.5 0.4 5.4 0.3 
Fasting glucose, mmol/l 4.8 0.4 4.7 0.4 4.8 0.4 4.9 0.5 4.8 0.4 4.8 0.4 4.8 0.6 
Insulin, pmol/la 39.0 31.5 31.0 25.0 52.0 40.0 43.5 28.0 42.0 44.0 33.0 30.0 36.0 18.0 
C-peptide, nmol/l
a
 0.61 0.36 0.57 0.31 0.73 0.35 0.64 0.36 0.53 0.32 0.53 0.35 0.55 0.26 
HOMA-IRa 1.3 0.8 1.2 0.7 1.6 0.8 1.4 0.8 1.2 0.8 1.2 0.8 1.2 0.6 
HOMA-β
a
 125.7 41.3 121.3 40.4 138.1 45.9 124.7 40.0 118.9 27.4 116.8 34.0 119.2 25.9 
a median, IQR 
 
 
Page 21 of 23
a)
H
O
M
A
-I
R
W
es
te
rn
 E
ur
op
e
So
ut
h 
As
ia
M
idd
le 
Ea
st
Su
b-
Sa
ha
ra
n 
Af
ric
a
Ea
st 
As
ia
Ot
he
rs
0.0
0.5
1.0
1.5
2.0
b)
H
O
M
A
-b
W
es
te
rn
 E
ur
op
e
So
ut
h 
As
ia
M
idd
le 
Ea
st
Su
b-
Sa
ha
ra
n 
Af
ric
a
Ea
st 
As
ia
Ot
he
rs
0
50
100
150
200
Visit 1
Visit 2
Page 22 of 23
a)
H
O
M
A
-I
R
GD
M
No
n-
GD
M
0.0
0.5
1.0
1.5
2.0
b)
H
O
M
A
-b
GD
M
No
n-
GD
M
0
50
100
150
200
Visit 1
Visit 2
Page 23 of 23
